A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 When PF614 Capsule is Co Administered With Nafamostat as a Combination IR Solution and ER Capsule Formulation in Healthy Subjects
Latest Information Update: 30 May 2025
At a glance
- Drugs PF 614 (Primary) ; Nafamostat; Naltrexone
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Ensysce Biosciences
Most Recent Events
- 25 May 2025 Planned End Date changed from 1 Dec 2025 to 27 Mar 2026.
- 25 May 2025 Planned primary completion date changed from 1 Sep 2025 to 30 Jan 2026.
- 10 Dec 2024 Status changed from not yet recruiting to recruiting.